Results support advancement of 10 mg dose into Phase 3 development End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 pilavapadin program at the 19th Annual Pain Therapeutics Summit. These... Read More

Diverse group of stakeholders aligned around the importance of elevating public awareness of need for new treatments for chronic pain and the need to expand the Alternatives to PAIN Act THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to enhance current and future legislative and... Read More

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting now expected during the fourth quarter THE WOODLANDS, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today... Read More

Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study THE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for its investigational, AAK1-inhibitor, pilavapadin, for the... Read More

Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19 th Annual Pain Summit THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data for its... Read More

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting expected by end of September THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that... Read More

THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc . (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9 th International Congress on Neuropathic Pain - (NeuPSIG) 2025. The findings highlight the... Read More

THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The... Read More

Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of clinical data was presented Sunday,... Read More

THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8 at 3:00 p.m. ET. The live events and replays of the presentations can be... Read More

Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET... Read More

THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq’s listing qualifications staff has determined that the closing bid price of the Company’s common stock has been at $1.00 per share or greater for ten consecutive business days and that, accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). This update was previously... Read More

THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access... Read More

Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of care will be presented at... Read More

Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis of... Read More

Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc . (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral... Read More

THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference, taking place in New York City on Thursday, June 5 at 12:50 p.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at... Read More

Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced details of its “ SO... Read More

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025... Read More

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page... Read More

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the... Read More

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.... Read More

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and... Read More

THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 in Miami on Wednesday, March 12, at 10:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at... Read More

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET THE WOODLANDS, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year... Read More

THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.... Read More

Pilavapadin achieved meaningful pain reduction versus placebo and was well-tolerated in the 10 mg dose, meeting the Company’s objectives for the study Advancement of 10 mg dose into Phase 3 development in DPNP supported by both PROGRESS and RELIEF DPN-1 studies, which collectively enrolled approximately 600 pilavapadin-treated patients Conference call and webcast at 8:00 a.m. ET THE WOODLANDS, Texas, March 03, 2025 (GLOBE... Read More

THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a conference call and webcast on Monday, March 3, 2025 at 8:00 a.m. ET to share topline results from the Phase 2b PROGRESS (A P hase 2b, Dose-ranging, R andomized, Double-blind, Placeb O -controlled, Parallel- GR oup, Multic E nter S tudy with an Open-label Extension in Patient S with... Read More

Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin THE WOODLANDS, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced The Lancet Diabetes & Endocrinology has published a research paper analyzing... Read More

THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain.” The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025. In advance of topline data from the Phase 2b PROGRESS trial anticipated later this quarter, the event will offer an... Read More

THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served... Read More

THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This expected... Read More

Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data Expected in Q1 2025 THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of patient enrollment in the PROGRESS (A P hase 2b, Dose-ranging, R andomized, Double-blind, Placeb O -controlled, Parallel- GR oup,... Read More

THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer and director, will present at two upcoming investor conferences in December. Piper Sandler 36 th Annual Healthcare Conference: Presentation Tuesday, December 3, 2024 at 8:00 am ET 7th Annual Evercore HealthCONx Conference:... Read More

Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions Prioritizing Strong R&D Pipeline Including Ongoing Studies in DPNP, HCM and Obesity Efforts Expected to Reduce 2025 Operating Costs by $100 Million Conference Call and Webcast at 9:00 am ET THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced... Read More

THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint... Read More

THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the American Heart Association’s (AHA) Sessions 2024 being held November 16-18 at McCormick Place Convention Center in Chicago, Illinois. One of those studies, a secondary analysis of data from the Phase 3 SCORED clinical trial, examined the... Read More

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024 Concluded Enrollment Screening For Phase 2b PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP); Topline Data Expected in Q1 2025 Executed Repositioning of INPEFA ® (sotagliflozin); Net Sales of $1.7... Read More

THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon management including Mike Exton, Lexicon’s chief executive officer and director will participate in a moderated discussion on Wednesday, November 20, 2024, at 9:00 am GT. A simultaneous webcast will be available in the “Events”... Read More

People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint, as people with T1D who do not have CKD Sotagliflozin was associated with a lower to neutral risk of severe hypoglycemia and did not significantly increase the risk of diabetic ketoacidosis (DKA) among a small number of DKA events THE WOODLANDS, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE)... Read More

THE WOODLANDS, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2024 financial results on Tuesday, November 12, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in Information U.S. Dial-in Number: (888)... Read More

Investigational New Drug (IND) application planned in 2025 for LX9851, a first-in-class, potent, selective, orally bioavailable molecule, as an anti-obesity agent Data from Lexicon’s Obesity Week presentations summarize the preclinical efficacy and mechanism of action of LX9851 THE WOODLANDS, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it will present data from two... Read More

THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the company’s New Drug Application (NDA) for Zynquista (sotagliflozin), an oral SGLT1/SGLT2 inhibitor, as an adjunct to insulin therapy for glycemic control in adults with... Read More

THE WOODLANDS, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new analysis of its Phase 3 SCORED clinical trial demonstrating the protective effects of sotagliflozin in patients with diabetic kidney disease (DKD). Data will be presented at Kidney Week 2024, the annual meeting of the American Society of Nephrology in San Diego, California. Previous analyses of the... Read More

Top-line Data Now Anticipated in Q1 2025 LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has closed screening and expects to complete enrollment ahead of schedule in PROGRESS (A P hase 2b, Dose-ranging, R andomized, Double-blind, Placeb O... Read More

THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viatris Inc. (Nasdaq: VTRS) has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the United States and Europe in all indications. Lexicon retains sole commercialization rights for sotagliflozin in all indications in the United States and Europe. Sotagliflozin was... Read More

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended to enable supplemental new drug application (sNDA) with a broad label in both obstructive and non-obstructive HCM THE WOODLANDS, Texas, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced... Read More

THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing. For the past 25 years, Mr. Wade has served in a series of finance, corporate development,... Read More

Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin TIR measures approach target set by American Diabetes Association Data to be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online THE WOODLANDS, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today... Read More

THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences taking place in September: H.C. Wainwright 26th Annual Global Investment Conference – Tuesday, September 10, 2024 at 12:30pm ET 2024 Cantor Fitzgerald Global Healthcare Conference – Tuesday, September 17, 2024 at 8:35am ET A... Read More

Results showed reductions in heart attack, stroke and heart failure events in all patients with even greater benefit for heart failure events among patients with longer diabetes duration New analysis further differentiates INPEFA among SGLT inhibitors THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post-hoc analysis of Phase 3 data from the SCORED... Read More

Advisory Committee Meeting Scheduled for October 31, 2024; PDUFA Goal Date Remains December 20, 2024 Lexicon Seeks Approval for ZYNQUISTA™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the U.S. Food and Drug Administration... Read More

Company to Focus on Targeted Promotion of INPEFA ® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™ Efforts Expected to Reduce 2025 Operating Costs by $40 Million THE WOODLANDS, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following a strategic review of its commercial and pipeline programs, it will refocus resources across... Read More

THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Posters will be displayed in the poster area of Exhibition Hall B... Read More

INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study of Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) Expect Topline Data in Q2 2025 from PROGRESS Phase 2b Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Conference Call and... Read More

THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in Information U.S. Dial-in Number: (888)... Read More

Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the... Read More

New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texas, July 15, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Journal of Managed Care + Specialty Pharmacy... Read More

THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis. “I am... Read More

Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early 2025 THE WOODLANDS, Texas, June 21, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following multiple interactions with and recent feedback from the U.S. Food and... Read More

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexicon’s dose-ranging Phase 2b PROGRESS trial, currently enrolling patients THE WOODLANDS, Texas, June 19, 2024 (GLOBE NEWSWIRE) -- Lexicon... Read More

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a... Read More

THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida. All three poster presentations will occur on Sunday, June 23, 12:30 - 1:30 p.m. ET, in the Poster... Read More

THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade, Lexicon’s president and chief financial officer and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion on Wednesday, June 5, 2024, at 3:00 pm ET. A... Read More

THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA ® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related events across a diverse population of patients, including patients with preserved ejection fraction (HFpEF). Researchers noted that INPEFA appeared... Read More

THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT (11:00 am ET). A simultaneous webcast will be available in the “Events” section of the Lexicon... Read More

Commercial launch of INPEFA ® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy, with enrollment expected to begin mid-year 2024 Enrollment in Phase 2b PROGRESS study of LX9211 in Diabetic Peripheral Neuropathic Pain on track for expected Q2... Read More

THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th anniversary with the company. The board of directors has initiated a search for a new chief executive officer which will consider both... Read More

THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in Information U.S. Dial-in Number: (888) 317-6003... Read More

THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024. The event will be held in New York City from 9:00 a.m. to 12:00 p.m. ET. Business and scientific updates will be presented by Lonnel Coats, Lexicon’s chief executive officer; Jeff Wade,... Read More

THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual... Read More

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American College of Cardiology 73rd Annual Scientific Session & Expo being held April 6 - 8, 2024 in Atlanta, Georgia, including results from a post-hoc... Read More

THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD). In this important patient population, treatment with sotagliflozin successfully... Read More

Commercial launch of INPEFA ® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of LX9211 in Diabetic Peripheral Neuropathic Pain; topline data anticipated Q2 2025 Preparations underway for Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy and resubmission of NDA for sotagliflozin in... Read More

THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity financing that is expected to result in gross proceeds of approximately $250 million, before deducting placement agent fees and offering expenses. Pursuant to the terms of the... Read More

Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in Patients with Type 1 Diabetes and Chronic Kidney Disease Resubmission is Anticipated Mid-2024 THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing to... Read More

INPEFA ® Launch Positioned for Acceleration in 2024 Clinical Data and FDA Feedback Support INPEFA Life Cycle Management Opportunity in Hypertrophic Cardiomyopathy LX9211 Late-Stage Development Underway, with Potential to Be First New Non-Opioid Drug for Diabetic Peripheral Neuropathic Pain in Over Two Decades Company Presentation January 11, 2024 at 10:30am PST (1:30pm ET) THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE)... Read More

THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024. Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation at 10:30am PT / 1:30 pm ET on Thursday, January 11 th . Jeff Wade, Lexicon’s president and chief financial officer,... Read More

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.... Read More

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35 th Annual Piper Sandler Healthcare Conference 6 th Annual Evercore ISI HealthCONx Conference Lonnel Coats, Lexicon’s chief executive officer, Jeff Wade, Lexicon’s president and chief financial officer, Tom... Read More

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12,... Read More

THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. ( Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023. Jeff Wade, Lexicon’s president and chief financial officer, and Tom Garner, Lexicon’s senior vice president and chief commercial officer, will make a company presentation at 5:00 pm GMT / 12:00 pm EST on... Read More

Commercial launch of INPEFA ® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community Significant formulary inclusions effective in Q4 opening the opportunity for further commercial acceleration into 2024 and beyond LX9211 moving into late-stage development for the treatment of diabetic peripheral neuropathic... Read More

THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8 th , 2023 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a business update. Dial-in Information U.S. Dial-in Number: (888)... Read More

Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that five data presentations related to INPEFA ®... Read More

As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of... Read More

Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and... Read More

Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to sotagliflozin, as well as data from a... Read More

Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP) INPEFA recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today highlighted upcoming presentations of two studies demonstrating positive financial impact of INPEFA ® (sotagliflozin) at the... Read More

Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of Managed Care & Specialty Pharmacy (JMCP) THE WOODLANDS, Texas, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that findings from two studies on the cost-effectiveness and budget... Read More

INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023 THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined... Read More

THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023. Mr. Garner has over 25 years of pharmaceutical industry experience, having started his career in the United Kingdom with roles of increasing seniority at Boehringer Ingelheim and Eli Lilly... Read More

INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase 3 cardiovascular outcomes studies that led to FDA approval THE WOODLANDS, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new analysis of clinical trial data for INPEFA ® (sotagliflozin) will be presented at the... Read More

INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain THE WOODLANDS, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced several upcoming Lexicon-supported data presentations related to heart failure (HF), type 1 diabetes (T1D), and diabetic peripheral... Read More

THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25 th Annual Global Investment Conference, taking place September 11-13, 2023. Jeffrey L. Wade, Lexicon’s president and chief financial officer, will make a company presentation at 5:00 pm ET on Tuesday, September 12 th . A simultaneous webcast of the... Read More

Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose optimization study planning underway, with initiation of dosing expected before the end of 2023, and extension to run in parallel with next-stage Phase 3 studies THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today... Read More

THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heart failure, as well as Lexicon-supported data relating to changing patterns of heart failure diagnoses, will be highlighted in two sessions during ESC Congress 2023, taking place August 25-28, 2023,... Read More

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of Approximately 50% Demonstrated for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge THE WOODLANDS, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced... Read More

INPEFA TM (sotagliflozin) receives FDA approval for the treatment of heart failure INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes LX9211 moving into late-stage development for the treatment of diabetic peripheral neuropathic pain Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Aug. 03, 2023... Read More

THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3 rd , 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in Information U.S. Dial-in Number: (888)... Read More

THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board of Directors. Ms. Sullivan brings extensive commercialization, strategy, and market access experience to the Lexicon Board of Directors. She was chief commercial officer of The Medicines Company until its acquisition by Novartis, and subsequently served as... Read More

First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies Feedback obtained from U.S. Food and Drug Administration (FDA) Conference Call and Webcast on Monday, June 26, 2023, at 8:00 am Eastern Time THE WOODLANDS, Texas, June 23, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational... Read More

LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE WOODLANDS, Texas, June 20, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc . (Nasdaq: LXRX) today announced that clinical study results relating to LX9211, its investigational drug for the treatment of diabetic peripheral neuropathic pain, and INPEFA™ (sotagliflozin),... Read More

INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to placebo in the SOLOIST-WHF study Conference Call and Webcast on Tuesday, May 30, 2023, at 8:00 am Eastern Time A Media... Read More

THE WOODLANDS, Texas, June 06, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies 2023 Global Healthcare Conference, taking place June 7-9, 2023. Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s president and chief financial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will... Read More

THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent private placement of shares of its common stock. The closing included the issuance and sale of an additional 3,588,705 shares of common stock to the underwriters pursuant to the full exercise of their option to purchase additional... Read More

THE WOODLANDS, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $2.60 per share. All of the shares are being... Read More

THE WOODLANDS, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no... Read More

INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to placebo in the SOLOIST-WHF study Conference Call and Webcast on Tuesday, May 30, 2023, at 8:00 am Eastern Time THE... Read More

Sotagliflozin reduced the risk of cardiovascular death and heart failure readmissions in patients hospitalized for worsening heart failure events in SOLOIST-WHF study Sotagliflozin NDA for treatment of heart failure on track for May 27, 2023 PDUFA action date THE WOODLANDS, Texas, May 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that results of a new investigator-initiated... Read More

NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key corporate milestones. “Our NDA for sotagliflozin for the treatment of heart failure is on track for its May... Read More

THE WOODLANDS, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in Information U.S. Dial-in Number: (888) 317-6003... Read More

THE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc . (Nasdaq: LXRX), today announced that results from RELIEF-PHN-1, a Phase 2 double-blind, placebo-controlled trial of its investigational drug LX9211 for the treatment of postherpetic neuralgia, will be presented during the Emerging Science session at the AAN Annual Meeting, April 22-27, in Boston, MA: RELIEF-PHN-1: A Phase 2 Double-Blind,... Read More

THE WOODLANDS, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. ( Nasdaq: LXRX) today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17-20, 2023. Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s president and chief financial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical... Read More

Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection fraction (LVEF) range THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational product sotagliflozin presented at the American... Read More

Emphasizes challenges faced by patients and clinicians within the first 30 days after discharge from a heart failure hospitalization Reinforces impact of rehospitalizations for heart failure patients and healthcare system Campaign launches at American College of Cardiology’s 72nd Annual Scientific Session Together with World... Read More

NDA for Sotagliflozin on Track for May 2023 PDUFA date following Late-Cycle Review Meeting LX9211 Demonstrates Consistent Results in Full Data from RELIEF-DPN-1 in Diabetic Peripheral Neuropathic Pain and Top-Line Data from RELIEF-PHN-1 in Post-Herpetic Neuralgia Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, March 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today... Read More

THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2022 financial results on Thursday, March 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in Information U.S. Dial-in Number: (888)... Read More

THE WOODLANDS, Texas, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology’s 72 nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana.... Read More

THE WOODLANDS, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 41 st Annual JP Morgan Healthcare Conference, taking place January 9-12, 2023. Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation which will be available on-demand beginning at 3:00 pm ET/12:00 pm PST on Thursday, January 12, 2023. A simultaneous webcast... Read More

LX9211 demonstrated clear evidence of effect, achieving Lexicon’s goal for the study of supporting advancement in another indication within neuropathic pain Consistent reduction in ADPS compared to placebo throughout dosing period, statistically significant when measured across dosing period, but not reaching significance at... Read More

Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6 Significant benefits demonstrated on burning pain and on pain interference with sleep No evidence of withdrawal symptoms or rebound pain after treatment ended Conference Call and Webcast Today at 5:00pm ET Hosted by Lexicon Management THE WOODLANDS, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF and SCORED Phase 3 outcomes studies of its investigational sotagliflozin product at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois. The following analyses of sotagliflozin have been selected for oral and poster presentations: “The effect of the dual SGLT1 and 2... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany: “Evaluation of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain: Study Design and Topline Results from the RELIEF-DPN-1 Trial”, describes the... Read More

Data presented at the Heart Failure Society of America annual scientific meeting New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failure Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes trial of sotagliflozin, an investigational... Read More

Poster and Oral Presentation at PAINWeek Describing a Novel Mechanism of Action for Neuropathic Pain Poster at International Association for the Study of Pain (IASP) World Congress on Pain Describing Design Elements of the RELIEF-DPN-1 Study Podium Presentation at 16 th Annual Pain Therapeutics Summit Discussing Full Results From the RELIEF-DPN-1 Study Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of... Read More

Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies Recent Publication in the Journal Diabetes Care Evaluates Metabolic, Intestinal and Cardiovascular Effects in a Clinical Study Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that sotagliflozin’s differentiated dual SGLT1 and... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001 (the “ Common Stock ”), pursuant to the full exercise of the underwriters’ option to purchase additional shares in connection with Lexicon’s previously announced public offering of Common Stock. After giving effect to the full exercise of the underwriters’... Read More

Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA, with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic Neuropathy, Promising Novel Mechanism of Action in Neuropathic Pain Conference Call and Webcast at 5:00 pm Eastern Time Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m. CT that day to discuss its financial and operating results and to provide a general business update. Dial-in Information Dial-in Number: (888) 886-7786 Conference ID: 78319165 Replay... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the “ Common Stock ”). The shares of Common Stock are being offered at a public offering price of $2.50 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001 (the “ Common Stock ”). In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of Common Stock. There can be no assurance as to whether or when the... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of heart failure. The FDA assigned a standard review for the NDA filing with a Prescription Drug User Fee Act (PDUFA) target action date in May 2023. “This is an... Read More

Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy Conference Call and Webcast at 8:00 a.m. Eastern Time June 30, 2022 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy. LX9211 achieved the primary... Read More

THE WOODLANDS, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET. A webcast of the event will be available in the “Events” section of the Lexicon website at www.lexpharma.com . An archived version of the webcast will be... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin for the treatment of heart failure. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. “The resubmission of our NDA places us a step closer to the... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones. “We plan to resubmit our New Drug Application (NDA) for sotagliflozin for the treatment of heart failure this month having received confirmation from the FDA in late April that it is aligned with our resubmission plans. With the recently announced loan facility, we... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET / 7:00 a.m. CT that day to discuss its financial and operating results and to provide a general business update. Dial-in Information U.S. Dial-in Number: (888) 645-5785 International Dial-in Number:... Read More

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will present at the 21 st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 8:45 a.m. ET. A webcast of the event will be available in the “Events” section of the Lexicon website at www.lexpharma.com . An archived version of the webcast will be available on the website... Read More

Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society of America New guidelines recommend the use of SGLT inhibitors for the prevention and treatment of heart failure and highlight the need to improve optimization of medical therapies during hospitalizations Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) welcomes new guidelines for the management of heart failure... Read More